FAQ: NanoViricides' NV-387 Anti-Measles Breakthrough and Clinical Progress
Summary
NanoViricides' lead drug candidate NV-387 demonstrated potent anti-Measles activity in preclinical studies, extending survival by 130% and protecting lung tissue in severe infection models. With no approved Measles treatments currently available, these findings highlight NV-387's broad-spectrum potential as it advances through clinical development.
What is the main announcement from NanoViricides regarding NV-387?
NanoViricides announced that their lead drug candidate NV-387 showed strong anti-Measles activity in both cell culture and humanized animal models, extending survival by 130% and protecting lung tissue in severe infection stages. This was discussed by CEO Dr. Anil Diwan in a Proactive interview available at https://youtu.be/m_3Yk4_832E.
Why is this anti-Measles finding significant?
This finding is significant because there are currently no approved treatments available for Measles, making NV-387’s potent anti-Measles activity particularly important. The results underscore the drug’s broad-spectrum potential against multiple viral infections.
What is the current clinical status of NV-387?
NV-387 has completed Phase I human trials with no reportable adverse events and is advancing to Phase II clinical trials for MPox. The drug has shown promising safety and efficacy profiles in early development stages.
What other viral infections is NanoViricides targeting with NV-387?
NanoViricides plans to develop NV-387 as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is also developing drugs against numerous other viral diseases including Herpes, HIV, Hepatitis C, and Ebola.
How is NanoViricides positioned to respond to urgent Measles cases?
NanoViricides is positioned to support FDA emergency use applications and investigator-initiated INDs (Investigational New Drug applications) for urgent Measles cases, allowing for potential accelerated access to the treatment in critical situations.
What is NanoViricides’ business model and technology foundation?
NanoViricides’ business model is based on licensing technology from TheraCour Pharma Inc. for specific antiviral applications. The company creates special purpose nanomaterials for antiviral therapy using their novel nanoviricide technology platform, which is based on intellectual property from TheraCour Pharma.
Where can I find more detailed information about this announcement?
The full press release is available at https://ibn.fm/uqiWa, and the company’s website at https://www.nanoviricides.com/ provides additional information about their technology and drug development programs.
What other advanced drug candidates does NanoViricides have in development?
In addition to NV-387, NanoViricides has another advanced drug candidate called NV-HHV-1 for the treatment of Shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials as their lead program.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 268743